UCBís Bimekizumab Expected to Reach Sales of $254.9m by 2027 After Positive Results for Psoriasis Patients

Wednesday, December 25, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

UCB recently announced positive results from its Phase III active-controlled psoriasis study BE SURE in which UCB compared the investigational dual interleukin (IL)-17A/F inhibitor bimekizumab to Humira (adalimumab) in adults with moderate-to-severe psoriasis. GlobalData a leading data and analytics company anticipates that bimekizumab will have a strong position in the psoriasis market supported by potent efficacy data from clinical trials. However as it will be the fourth IL-17 anticipated to launch in the market bimekizumab is expected to garner sales of $254.9m by 2027. UCB already has Cimzia (certolizumab pegol) an anti-tumor necrosis factor drug approved for psoriasis.

Vikesh Devlia PhD Immunology Analyst at GlobalData comments: GlobalData believes that UCB is focusing heavily on the dual action of bimekizumab as a point of differentiation which will be important due to the therapyís late entry into the psoriasis market and in the anti-IL-17 class.Ē

The BE SURE study is one of six ongoing clinical trials of bimekizumab in psoriasis and is UCBís third study that has shown positive results this year. The BE VIVID study which read out in October demonstrated bimekizumabís superiority compared to Janssenís Stelara (ustekinumab). The BE READY study which read out in November met its co-primary endpoints of 90% improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1) at Week 16 compared to placebo.

In the BE SURE study the co-primary endpoints at week 16 were met demonstrating bimekizumabís superiority to Humira. Patients treated with bimekizumab achieved PASI 90 and IGA 0/1 compared to Humira. The BE SURE study also met all of its ranked secondary endpoints with statistical significance including superior total skin clearance at Weeks 16 and 24 as measured by PASI 100 compared to Humira. Additionally bimekizumab was found to be statistically superior to Humira in achieving rapid response at four weeks post-treatment for PASI 75. During the dose-blind maintenance period high levels of skin clearance were maintained with bimekizumab through Week 56 post-treatment.

The continued data assessment indicates that bimekizumabís safety profile was consistent with earlier clinical studies. Complete BE SURE results will be presented in 2020 and will give an in-depth view of the drug compared to Humira.

Devlia concludes: ďGlobalData anticipates UCB will hold a large overall share of the psoriasis markets once bimekizumab launches. UCB is expected to increase its marketing efforts and infiltrate the psoriasis market from various points in order to ramp up sales in the coming years.Ē


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store